Camber Capital Management’s Pfizer PFE Stock Holding History

Camber Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$36.4M	Sell	1,500,000 -1,000,000	-40%	-$23.3M	3.41%	11
2025 Q1	$63.4M	Sell	2,500,000 -2,500,000	-50%	-$65.4M	2.25%	12
2024 Q4	$133M	Buy	+5,000,000	New	+$136M	3.07%	12

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Camber Capital Management's PFE Position: Q2 2025 in Review

Camber Capital Management reduced its Pfizer (PFE) stake by 40% in Q2 2025, selling an estimated $23.3M and leaving 1,500,000 shares worth $36.4M. The position accounts for 3.41% of the portfolio, ranked #11.

Camber Capital Management first reported a position in PFE in Q4 2024 and has held it in 3 quarters since. The position peaked at $133M in Q4 2024. 2,813 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

Camber Capital Management held 1,500,000 shares of Pfizer worth $36.4M as of Q2 2025.
Camber Capital Management sold 1,000,000 Pfizer shares in Q2 2025, an estimated $23.3M.
Pfizer made up 3.41% of Camber Capital Management's portfolio in Q2 2025, its #11 holding.
Camber Capital Management first reported a position in Pfizer in Q4 2024 and has held it in 3 quarters since.
Camber Capital Management's Pfizer position peaked at $133M in Q4 2024.
2,813 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.